JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Viatris Inc

Geschlossen

BrancheGesundheitswesen

10.36 0.58

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.3

Max

10.49

Schlüsselkennzahlen

By Trading Economics

Einkommen

3B

-4.6M

Verkäufe

328M

3.6B

Dividendenrendite

4.72

Gewinnspanne

-0.128

Angestellte

32,000

EBITDA

2.9B

578M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+10.47% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.72%

2.33%

Nächstes Ergebnis

6. Nov. 2025

Nächste Dividendenausschüttung

12. Dez. 2025

Nächstes Ex-Dividendendatum

21. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.5B

12B

Vorheriger Eröffnungskurs

9.78

Vorheriger Schlusskurs

10.36

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Viatris Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Okt. 2025, 09:10 UTC

Heiße Aktien

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

Peer-Vergleich

Kursveränderung

Viatris Inc Prognose

Kursziel

By TipRanks

10.47% Vorteil

12-Monats-Prognose

Durchschnitt 11.5 USD  10.47%

Hoch 15 USD

Tief 8 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Viatris Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

1

Buy

2

Halten

1

Sell

Technischer Score

By Trading Central

8.48 / N/AUnterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Strong Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat